We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

284 hedge funds and large institutions have $8.18B invested in Sage Therapeutics in 2019 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 100 increasing their positions, 94 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 31

4% more funds holding

Funds holding: 272 → 284 (+12)

6% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 94

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

0.74% less ownership

Funds ownership: 113.57% → 112.84% (-0.74%)

17% less call options, than puts

Call options by funds: $102M | Put options by funds: $124M

23% less capital invested

Capital invested by funds: $10.6B → $8.18B (-$2.46B)

Holders
284
Holders Change
+12
Holders Change %
+4.41%
% of All Funds
6.23%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
44
Increased
100
Reduced
94
Closed
31
Calls
$102M
Puts
$124M
Net Calls
-$21.6M
Net Calls Change
+$36.9M

Top Buyers

Rank Fund Capital Flow
1
Capital International Investors
Capital International Investors
California
+$86.4M
2
PHS
PFM Health Sciences
California
+$62.5M
3
Viking Global Investors
Viking Global Investors
Connecticut
+$44.1M
4
CII
Capital International Inc
California
+$41.7M
5
American Century Companies
American Century Companies
Missouri
+$34.4M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$73.7M
2
FCM
Frontier Capital Management
Massachusetts
-$43M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$42.9M
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$39.9M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$33.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
126
Profund Advisors
Maryland
$1.67M -$119K -713 -6%
CIS
127
Capital International Sarl
California
$1.54M +$1.84M +11,000 New
CM
128
Castleark Management
Illinois
$1.51M +$561K +3,355 +45%
Mirae Asset Global Investments
129
Mirae Asset Global Investments
South Korea
$1.49M +$82.5K +493 +5%
SAM
130
Sectoral Asset Management
Quebec, Canada
$1.47M -$2.33M -13,900 -57%
Bank of Montreal
131
Bank of Montreal
Ontario, Canada
$1.46M -$781K -4,668 -31%
SGH
132
Sivik Global Healthcare
Connecticut
$1.4M -$1.25M -7,500 -43%
Hudson Bay Capital Management
133
Hudson Bay Capital Management
Connecticut
$1.4M – – –
Squarepoint
134
Squarepoint
New York
$1.35M +$1.61M +9,645 New
ARTA
135
A.R.T. Advisors
New York
$1.34M +$1.6M +9,571 New
URS
136
Utah Retirement Systems
Utah
$1.33M +$16.7K +100 +1%
Walleye Capital
137
Walleye Capital
New York
$1.29M +$1.54M +9,199 New
Mackenzie Financial
138
Mackenzie Financial
Ontario, Canada
$1.2M +$11.9K +71 +0.8%
Jane Street
139
Jane Street
New York
$1.15M +$957K +5,718 +229%
XK
140
Xact Kapitalforvaltning
Sweden
$1.14M – – –
Public Employees Retirement Association of Colorado
141
Public Employees Retirement Association of Colorado
Colorado
$1.12M – – –
Comerica Bank
142
Comerica Bank
Texas
$1.07M +$953K +5,695 +302%
TAM
143
Tiverton Asset Management
Delaware
$1.06M – – –
AG
144
Aperio Group
California
$1.06M +$3.51K +21 +0.3%
FAM
145
Fred Alger Management
New York
$1.05M +$83.6K +500 +7%
LP
146
LMR Partners
United Kingdom
$1.05M +$1.25M +7,500 New
Asset Management One
147
Asset Management One
Japan
$1.01M +$685K +4,096 +131%
State of Wisconsin Investment Board
148
State of Wisconsin Investment Board
Wisconsin
$1M -$9.03K -54 -0.8%
Parallax Volatility Advisers
149
Parallax Volatility Advisers
California
$971K +$217K +1,299 +23%
BC
150
Brinker Capital
Pennsylvania
$942K +$40.1K +240 +4%
4 5
6
7 8

SAGE Hedge Fund Activity: Q3 2019 in Review

284 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2019, worth a combined $8.18B — down 23% from $10.6B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new SAGE positions and 31 closed out — a net gain of 13 holders — while 100 added to existing stakes and 94 trimmed.

The largest buyer was Capital International Investors, adding an estimated $86.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $73.7M.

  • 284 institutional investors held Sage Therapeutics (SAGE) as of Q3 2019, up from 272 in Q2 2019.
  • Funds reported $8.18B of Sage Therapeutics stock for Q3 2019, down 23% quarter-over-quarter.
  • 44 funds opened new Sage Therapeutics positions in Q3 2019 and 31 closed out, a net change of +13 holders.
  • The largest Sage Therapeutics buyer in Q3 2019 was Capital International Investors, an estimated $86.4M added.
  • The largest Sage Therapeutics seller in Q3 2019 was T. Rowe Price Associates, an estimated $73.7M sold.

Based on aggregated 13F filings for Q3 2019.